{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Percentage change in growth of in vitro myeloma cells from baseline to end of study.","groups":[{"description":"Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day.\n\nrecombinant interferon-α\n\nrecombinant interleukin-6","id":"OG000","title":"Interleukin-6 and Interferon-α"}],"populationDescription":"Zero participants tolerated protocol therapy and the research sample blood draws were therefore not completed as planned. Because of this, the data from this outcome could not be collected.","reportingStatus":"POSTED","timeFrame":"Day 0, Day 14, Months 1, 2, 4, and 6 of combined therapy, and end of study","title":"Impact of Treatment on Growth of Myeloma Cells","type":"PRIMARY"}